|
|
 Previous Article | Table of Contents | Next Article 
Increased Frequency of Expression of Elevated Dihydrofolate Reductase in T-Cell Versus B-Precursor Acute Lymphoblastic Leukemia in Children
Larry H. Matherly,
Jeffrey W. Taub,
So C. Wong,
Pippa M. Simpson,
Rachenii Ekizian,
Steve Buck,
Michael Williamson,
Michael Amylon,
Jeannette Pullen,
Bruce Camitta, and
Y. Ravindranath
From the Experimental and Clinical Therapeutics Program, Barbara Ann Karmanos Cancer Institute, the Department of Pharmacology, and the Department of Pediatrics, Wayne State University School of Medicine, the Children's Hospital of Michigan, Detroit, MI; and the Pediatric Oncology Group, Chicago, IL.
The relationships between dihydrofolate reductase (DHFR) levels or methotrexate membrane transport and acute lymphoblastic leukemia (ALL) immunophenotype were evaluated on 51 T-cell and 44 B-precursor ALL specimens from 90 pediatric ALL patients at diagnosis and relapse, using a fluorescent methotrexate analog (PT430) and flow cytometry assay (Matherly et al, Blood 85:500, 1995). For T-cell ALL, 35 of 45 (78%) of newly diagnosed patients' specimens exhibited elevated DHFR relative to DHFR levels in ALL blasts from methotrexate-responsive patients. For 30 of 45 diagnostic T-ALL specimens, DHFR expression was heterogeneous, with up to 3 separate subpopulations covering a 44-fold range; the DHFR-overproducing fractions comprised 10% to 88% of the total blasts. Elevated DHFR was less common in B-precursor ALL at diagnosis, being detected in only 17 of 36 specimens (47%); 11 of these samples exhibited DHFR heterogeneity. Median maximal DHFR levels were fourfold higher in T-cell than B-precursor ALL at diagnosis. Within a particular phenotypic group, there were no correlations between DHFR levels and patient prognostic features, including age, sex, chromosomal abnormalities, white blood cell counts (WBCs), and percentage of S-phase. However, for B-precursor ALL, there was a notably higher fraction of African-American than white patients with elevated DHFR. For patients (both phenotypes) with low WBCs (<50,000/µL), event-free survival times were significantly shorter for those expressing DHFR above a threshold level than for patients expressing DHFR below this level (P < .016); this relationship was not seen for patients with high WBCs (<50,000/µL). Elevated DHFR was detected in 11 of 14 relapse specimens (5 of 6 T-cell and 6 of 8 B-precursor). Two of five paired relapse specimens (both T-cell) from patients treated with methotrexate exhibited increased DHFR levels over those at diagnosis (2.5- to 5-fold); the fraction of DHFR-overproducing blasts was also increased in 4 of 5 paired relapse specimens (2 B-precursor and 2 T-cell). In contrast to the variations in DHFR, highly impaired methotrexate transport was detected in only 6 of 95 ALL specimens, including both diagnosis and relapse. There was no correlation between phenotype and impaired transport. These data provide further rationale for the use of mechanistically based prognostic factors to complement known biologic or disease-based prognostic indicators in the design of ALL therapy including methotrexate, particularly with patients presenting with low WBCs. The finding of a markedly increased frequency of DHFR overexpression in T-cell over B-precursor ALL suggests that this difference is associated with the poorer prognosis of patients with T-cell ALL treated with standard-dose antimetabolite therapy and implies that higher-dose methotrexate ( 1 g/m2) during consolidation therapy may be useful in the treatment of this disease.
Blood, Vol. 90 No. 2 (July 15), 1997:
pp. 578-589
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Al-Shakfa, S. Dulucq, I. Brukner, I. Milacic, M. Ansari, P. Beaulieu, A. Moghrabi, C. Laverdiere, S. E. Sallan, L. B. Silverman, et al.
DNA Variants in Region for Noncoding Interfering Transcript of Dihydrofolate Reductase Gene and Outcome in Childhood Acute Lymphoblastic Leukemia
Clin. Cancer Res.,
November 15, 2009;
15(22):
6931 - 6938.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. French, W. Yang, C. Cheng, S. C. Raimondi, C. G. Mullighan, J. R. Downing, W. E. Evans, C.-H. Pui, and M. V. Relling
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia
Blood,
May 7, 2009;
113(19):
4512 - 4520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Bertino
Transfer of drug resistance genes into hematopoietic stem cells for marrow protection.
Oncologist,
October 1, 2008;
13(10):
1036 - 1042.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dulucq, G. St-Onge, V. Gagne, M. Ansari, D. Sinnett, D. Labuda, A. Moghrabi, and M. Krajinovic
DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL
Blood,
April 1, 2008;
111(7):
3692 - 3700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. von Stackelberg, R. Hartmann, C. Buhrer, R. Fengler, G. Janka-Schaub, A. Reiter, G. Mann, K. Schmiegelow, R. Ratei, T. Klingebiel, et al.
High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia
Blood,
March 1, 2008;
111(5):
2573 - 2580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Matheson, L. A. Hogarth, M. C. Case, J. A.E. Irving, and A. G. Hall
DHFR and MSH3 co-amplification in childhood acute lymphoblastic leukaemia, in vitro and in vivo
Carcinogenesis,
June 1, 2007;
28(6):
1341 - 1346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Liu, Y. Ge, S. G. Payton, A. Aboukameel, S. Buck, R. M. Flatley, C. Haska, R. Mohammad, J. W. Taub, and L. H. Matherly
Transcriptional Regulation of the Human Reduced Folate Carrier in Childhood Acute Lymphoblastic Leukemia Cells
Clin. Cancer Res.,
January 15, 2006;
12(2):
608 - 616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Flatley, S. G. Payton, J. W. Taub, and L. H. Matherly
Primary Acute Lymphoblastic Leukemia Cells Use a Novel Promoter and 5'Noncoding Exon for the Human Reduced Folate Carrier That Encodes a Modified Carrier Translated from an Upstream Translational Start
Clin. Cancer Res.,
August 1, 2004;
10(15):
5111 - 5122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, J. T. Sandlund, D. Pei, G. K. Rivera, S. C. Howard, R. C. Ribeiro, J. E. Rubnitz, B. I. Razzouk, M. M. Hudson, C. Cheng, et al.
Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children
JAMA,
October 15, 2003;
290(15):
2001 - 2007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Whetstine, A. J. Gifford, T. Witt, X. Y. Liu, R. M. Flatley, M. Norris, M. Haber, J. W. Taub, Y. Ravindranath, and L. H. Matherly
Single Nucleotide Polymorphisms in the Human Reduced Folate Carrier: Characterization of a High-Frequency G/A Variant at Position 80 and Transport Properties of the His27 and Arg27 Carriers
Clin. Cancer Res.,
November 1, 2001;
7(11):
3416 - 3422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. H. Pollock, M. R. DeBaun, B. M. Camitta, J. J. Shuster, Y. Ravindranath, D. J. Pullen, V. J. Land, D. H. Mahoney Jr, S. J. Lauer, and S. B. Murphy
Racial Differences in the Survival of Childhood B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study
J. Clin. Oncol.,
February 14, 2000;
18(4):
813 - 813.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Rots, R. Pieters, G. J. Peters, C. H. van Zantwijk, R. Mauritz, P. Noordhuis, J. C. Willey, K. Hahlen, U. Creutzig, G. Janka-Schaub, et al.
Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates
Blood,
November 1, 1999;
94(9):
3121 - 3128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Guo, J. H. Healey, P. A. Meyers, M. Ladanyi, A. G. Huvos, J. R. Bertino, and R. Gorlick
Mechanisms of Methotrexate Resistance in Osteosarcoma
Clin. Cancer Res.,
March 1, 1999;
5(3):
621 - 627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Rots, R. Pieters, G.-J. L. Kaspers, C. H. van Zantwijk, P. Noordhuis, R. Mauritz, A. J.P. Veerman, G. Jansen, and G. J. Peters
Differential Methotrexate Resistance in Childhood T- Versus Common/PreB-Acute Lymphoblastic Leukemia Can Be Measured by an In Situ Thymidylate Synthase Inhibition Assay, But Not by the MTT Assay
Blood,
February 1, 1999;
93(3):
1067 - 1074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
